TROCAI (Tropism Coreceptor Assay Information): A new phenotypic tropism test and its correlation with trofile enhanced sensitivity and genotypic approaches

Journal of Clinical Microbiology

Volumn 48, Issue 12, 2010, Pages 4453-4458

  Gonzalez Serna, Alejandro ^a   Leal, Manuel ^a   Genebat, Miguel ^a   Abad, Maria Antonia ^a   Garcia Perganeda, Antonio ^a   Ferrando Martinez, Sara ^a   Ruiz Mateos, Ezequiel ^a  

^a Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MARAVIROC; VIRUS RNA;

ADULT; ALGORITHM; ARTICLE; CLINICAL ARTICLE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION TECHNOLOGY; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TROFILE ENHANCED SENSITIVITY; TROPISM CORECEPTOR ASSAY INFORMATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CYCLOHEXANES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TRIAZOLES; VIRAL TROPISM; VIRUS CULTIVATION;

EID: 78650038462     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00953-10     Document Type: Article

References (28)

1. Archer, J., M. S. Braverman, B. E. Taillon, B. Desany, I. James, P. R. Harrigan, M. Lewis, and D. L. Robertson. 2009. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23:1209-1218.
2. Berger, E. A., R. W. Doms, E. M. Fenyö, B. T. Korber, D. R. Littman, J. P. Moore, Q. J. Sattentau, H. Schuitemaker, J. Sodroski, and R. A. Weiss. 1998. A new classification for HIV-1. Nature 391:240.
3. Chueca, N., C. Garrido, M. Alvarez, E. Poveda, J. de Dios Luna, N. Zahonero, J. Hernández-Quero, V. Soriano, C. Maroto, C. de Mendoza, and F. García. 2009. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J. Med. Virol. 81:763-767.
4. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-13197.
5. Coakley, E., J. D. Reeves, W. Huang, M. Mangas-Ruiz, I. Maurer, A. M. Harskamp, S. Gupta, Y. Lie, C. J. Petropoulos, H. Schuitemaker, and A. B. van 't Wout. 2009. Comparison of the HIV-1 tropism profiles in clinical samples by the Trofile and MT-2 cell assays. Antimicrob. Agents Chemother. 53:4686-4693.
6. Delobel, P., M. T. Nugeyre, M. Cazabat, C. Pasquier, B. Marchou, P. Massip, F. Barre-Sinoussi, N. Israël, and J. Izopet. 2007. Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J. Clin. Microbiol. 45:1572-1580.
7. de Mendoza, C., K. Van Baelen, E. Poveda, E. Rondelez, N. Zahonero, L. Stuyver, C. Garrido, J. Villacian, V. Soriano, and the Spanish HIV Seroconverter Study Group. 2008. Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. J. Acquir. Immune Defic. Syndr. 48:241-244.
8. Demeter, L. M., R. J. Bosch, R. W. Coombs, S. Fiscus, J. Bremer, V. A. Johnson, A. Erice, J. B. Jackson, S. A. Spector, K. M. Squires, M. A. Fischl, M. D. Hughes, and S. M. Hammer. 2002. Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J. Clin. Microbiol. 40:2089-2094.
9. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
10. Genebat, M., E. Ruiz-Mateos, J. A. León, A. González-Serna, I. Pulido, I. Rivas, S. Ferrando, B. Sanchez, M. A. Muñoz, and M. Leal. 2009. Correlation between Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients. J. Antimicrob. Chemother. 64:845-849.
11. Genebat, M., E. Ruiz-Mateos, I. Pulido, A. González-Serna, A. García-Pergañeda, G. Méndez, M. C. Romero-Sánchez, S. Ferrando-Martínez, and M. Leal. 2010. Long-term immunovirological effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr. HIV Res. 8:482-486.
12. Hammer, S. M., J. J. Eron, Jr., P. Reiss, R. T. Schooley, M. A. Thompson, S. Walmsley, P. Cahn, M. A. Fischl, J. M. Gatell, M. S. Hirsch, D. M. Jacobsen, J. S. Montaner, D. D. Richman, P. G. Yeni, P. A. Volberding, and the International AIDS Society-USA. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300:555-570.
13. Hosoya, N., Z. Su, T. Wilkin, R. M. Gulick, C. Flexner, M. D. Hughes, P. R. Skolnik, F. Giguel, W. L. Greaves, E. Coakley, and D. R. Kuritzkes. 2009. Assessing HIV-1 tropism: a comparison of assays using replication competent virus versus plasma-derived pseudotyped virions. J. Clin. Microbiol. 47:2604-2606.
14. Huang, W., J. Toma, S. Fransen, E. Stawiski, J. D. Reeves, J. M. Whitcomb, N. Parkin, and C. J. Petropoulos. 2008. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J. Virol. 82:5584-5593.
15. Landovitz, R. J., J. B. Angel, C. Hoffmann, H. Horst, M. Opravil, Long J., W. Greaves, and G. Fätkenheuer. 2008. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 198:1113-1122.
16. Low, A. J., W. Dong, D. Chan, T. Sing, R. Swanstrom, M. Jensen, S. Pillai, B. Good, and P. R. Harrigan. 2007. Current V3 genotyping algorithms are inadequate for predicting X4 coreceptor usage in clinical isolates. AIDS 21:F17-F24.
17. Markowitz, M., M. Vesanen, K. Tenner-Racz, Y. Cao, J. M. Binley, A. Talal, A. Hurley, X. Jin, M. R. Chaudhry, M. Yaman, S. Frankel, M. Heath- Chiozzi, J. M. Leonard, J. P. Moore, P. Racz, D. F. Nixon, and D. D. Ho. 1999. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J. Infect. Dis. 179:527-537.
18. Poveda, E., E. Seclén, M. del Mar González, F. García, N. Chueca, A. Aguilera, J. J. Rodríguez, J. González-Lahoz, and V. Soriano. 2009. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J. Antimicrob. Chemother. 63:1006-1010.
19. Raymond, S., P. Delobel, M. Mavigner, M. Cazabat, C. Souyris, K. Sandres-Sauné, L. Cuzin, B. Marchou, P. Massip, and J. Izopet. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11-F16.
20. Reeves, J. D., E. Coakley, C. J. Petropoulos, and J. M. Whitcomb. 2009. An enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3:94-102.
21. Ruiz-Mateos, E., A. Pelchen-Matthews, M. Deneka, and M. Marsh. 2008. CD63 is not required for production of infectious human immunodeficiency virus type 1 in human macrophages. J. Virol. 82:4751-4761.
22. Ruiz-Mateos, E., A. Rubio, A. Vallejo, R. De la Rosa, A. Sanchez-Quijano, E. Lissen, and M. Leal. 2004. Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART). Clin. Exp. Immunol. 136:501-506.
23. Schürmann, D., G. Fätkenheuer, J. Reynes, C. Michelet, F. Raffi, J. van Lier, M. Caceres, A. Keung, A. Sansone-Parsons, L. M. Dunkle, and C. Hoffmann. 2007. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 21:1293-1299.
24. Trouplin, V., F. Salvatori, F. Cappello, V. Obry, A. Brelot, N. Heveker, M. Alizon, G. Scarlatti, F. Clavel, and F. Mammano. 2001. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 75:251-259.
25. Vallejo, A., E. Ruiz-Mateos, S. Molina-Pinelo, N. Soriano-Sarabia, B. de Felipe, S. Gutierrez, A. Sánchez-Quijano, E. Lissen, and M. Leal. 2006. Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure. Viral Immunol. 19:759-767.
26. Verhofstede, C., L. Vandekerckhove, V. V. Eygen, E. Demecheleer, I. Vandenbroucke, B. Winters, J. Plum, D. Vogelaers, and L. Stuyver. 2009. CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA. J. Acquir. Immune Defic. Syndr. 50:126-136.
27. Whitcomb, J. M., W. Huang, S. Fransen, K. Limoli, J. Toma, T. Wrin, C. Chappey, L. D. Kiss, E. E. Paxinos, and C. J. Petropoulos. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
28. Wong, J. K., M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.